UK drug major GlaxoSmithKline has decided not to exercise its option to license the candidate diabetic nephropathy drug XL784 from US biotechnology firm Exelixis, following the compound's failure to achieve primary efficacy endpoints in a Phase II study.
Exelixis said that said that, while it has no plans to invest further in XL784's development, it will begin seeking a partner with which to take the compound forward.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze